HTA60 Icosapent Ethyl in Addition to Statins Is a Cost-Effective Treatment in Patients at High Cardiovascular Risk With Elevated Triglycerides and Established Cardiovascular Disease or Diabetes With Risk Factor in the Netherlands

Autor: Pronk, LM, Piena, M, Van de Pas, M, Jakouloff, D, Giesen, E

Publikováno v: In Value in Health December 2022 25(12) Supplement:S308-S308

Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.

Autor: Verhaart SL; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom., Abu-Ghanem Y; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Mulder SF; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Oosting S; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands., Van Der Veldt A; Department of Medical Oncology, Erasmus Medical Center-Cancer Institute, Rotterdam, The Netherlands., Osanto S; Department of Medical Oncology, Leids University Medical Center, Leiden, The Netherlands., Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., Houtsma D; Department of Medical Oncology, HAGA Hospital, The Hague, The Netherlands., Peters FPJ; Department of Medical Oncology, Zuyderland Hospital, Sittard - Geleen, The Netherlands., Groenewegen G; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Pronk LM; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Tascilar M; Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis and Vllietland, Rotterdam, The Netherlands., Los M; Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, The Netherlands., Vreugdenhil G; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Polee M; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Ten Tije AJ; Department of Medical Oncology, Amphia Hospital, Breda, The Netherlands., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bex A; Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: axel.bex@nhs.net., van den Eertwegh AJ; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2021 Jun; Vol. 19 (3), pp. 274.e1-274.e16. Date of Electronic Publication: 2020 Oct 14.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Autor: Rozeman EA; The Netherlands Cancer Institute, Amsterdam, Netherlands., Menzies AM; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., van Akkooi ACJ; The Netherlands Cancer Institute, Amsterdam, Netherlands., Adhikari C; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia., Bierman C; The Netherlands Cancer Institute, Amsterdam, Netherlands., van de Wiel BA; The Netherlands Cancer Institute, Amsterdam, Netherlands., Scolyer RA; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Krijgsman O; The Netherlands Cancer Institute, Amsterdam, Netherlands., Sikorska K; The Netherlands Cancer Institute, Amsterdam, Netherlands., Eriksson H; Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden., Broeks A; The Netherlands Cancer Institute, Amsterdam, Netherlands., van Thienen JV; The Netherlands Cancer Institute, Amsterdam, Netherlands., Guminski AD; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Acosta AT; The Netherlands Cancer Institute, Amsterdam, Netherlands., Ter Meulen S; The Netherlands Cancer Institute, Amsterdam, Netherlands., Koenen AM; The Netherlands Cancer Institute, Amsterdam, Netherlands., Bosch LJW; The Netherlands Cancer Institute, Amsterdam, Netherlands., Shannon K; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Pronk LM; The Netherlands Cancer Institute, Amsterdam, Netherlands., Gonzalez M; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia., Ch'ng S; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Grijpink-Ongering LG; The Netherlands Cancer Institute, Amsterdam, Netherlands., Stretch J; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Heijmink S; The Netherlands Cancer Institute, Amsterdam, Netherlands., van Tinteren H; The Netherlands Cancer Institute, Amsterdam, Netherlands., Haanen JBAG; The Netherlands Cancer Institute, Amsterdam, Netherlands., Nieweg OE; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Klop WMC; The Netherlands Cancer Institute, Amsterdam, Netherlands., Zuur CL; The Netherlands Cancer Institute, Amsterdam, Netherlands., Saw RPM; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., van Houdt WJ; The Netherlands Cancer Institute, Amsterdam, Netherlands., Peeper DS; The Netherlands Cancer Institute, Amsterdam, Netherlands., Spillane AJ; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Hansson J; Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden., Schumacher TN; The Netherlands Cancer Institute, Amsterdam, Netherlands., Long GV; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia., Blank CU; The Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: c.blank@nki.nl.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2019 Jul; Vol. 20 (7), pp. 948-960. Date of Electronic Publication: 2019 May 31.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.